Teal Health Raises $22M for At-Home Cervical Screening

Teal Health has raised a $22M Series A at the point when its at-home cervical cancer screening business is shifting from a device launch into a national care-delivery test. The September 22, 2026 round was led by .406 Ventures, with continued backing from Emerson Collective, managed by Yosemite, Forerunner, and Serena Ventures, plus new participation from MPower Partners.

The financing brings Teal Health’s company-reported total funding to $45M. It gives the San Francisco company more capital to connect prescribing, kit fulfillment, laboratory testing, reimbursement, results, and follow-up around the Teal Wand, its FDA-authorized at-home vaginal self-collection device for cervical cancer screening. The broader question is whether a clinically validated product can become routine preventive care once insurance coverage expands in 2027.

What Teal Health Raised and Who Backed It

Teal Health announced the $22M Series A on September 22. .406 Ventures led the round. Emerson Collective, managed by Yosemite, Forerunner, and Serena Ventures returned, while Japan-based MPower Partners joined as a new investor. Teal did not disclose its valuation, ownership percentages, the security used, or any board changes.

The round follows an $8.8M seed announced in January 2023 and an additional $10M seed financing in January 2025. Teal reported $23M in total funding after the 2025 close, which makes the new $45M total consistent with the Series A. Labcorp participated in the 2025 financing, but Teal’s official September 2026 announcement does not list it in the current round.

Teal Health was founded in 2020 by CEO Kara Egan and Avnesh “Ave” Thakor, MD, PhD. Egan’s background spans health-tech investing and software operations, while Thakor is an interventional radiologist and translational scientist. The company’s current leadership page also names Sarah Rose as COO; it does not identify a CTO.

From FDA Authorization to National Access

The Teal Wand changes where a cervical screening sample can be collected. A patient completes a brief virtual visit, receives a prescribed kit, collects a vaginal sample at home, mails it to a laboratory for high-risk HPV testing, and receives results through a secure portal. Teal’s care model also provides follow-up navigation when a result requires additional clinical attention.

Teal received FDA De Novo authorization for the at-home self-collection device in May 2025 and launched nationwide availability across all 50 states in January 2026. Authorization applies to the collection pathway and its intended use; it should not be confused with a claim that every patient can replace every in-clinic exam. Eligibility, prescription, laboratory testing, results review, and appropriate follow-up remain part of the care process.

The supporting clinical evidence is unusually important because the product asks patients and clinicians to trust a different collection setting. In the SELF-CERV validation study indexed by PubMed, 609 screening-eligible participants were recruited across 16 U.S. sites. Among 582 evaluable paired samples, the positive percentage agreement between self-collected and clinician-collected samples for high-risk HPV was 95.2%. Clinical sensitivity for high-grade cervical dysplasia was 95.8%, equivalent to clinician collection in relative sensitivity.

Reimbursement Becomes the Distribution Layer

Teal says it has screened thousands of women nationally and that 59% of its users were underscreened before choosing its service. The company also reports an average 4.95/5 rating from thousands of users. Those figures are company-reported rather than independently audited, but they describe the population Teal is trying to reach: people for whom appointment availability, time, discomfort, trauma, or care access can make routine screening difficult.

The Series A arrives before a scheduled reimbursement change. Updated federal women’s preventive-services guidance is expected to require most health plans to cover self-collected cervical cancer screening and necessary follow-up without patient cost sharing for plan years beginning in 2027. That timing changes the commercial problem. Teal no longer has to rely only on consumers buying a better experience; it can work toward embedding the service in benefits, provider workflows, and health-system screening programs.

Teal plans to use the capital to expand payer, health-system, employer, provider, and brand partnerships, broaden direct-purchase options, and hire across clinical, commercial, technology, and operational functions. Each channel carries a different integration burden. A health system needs clinical coordination and records. A payer needs billing logic. An employer needs a benefits pathway. A direct purchaser needs clear eligibility, fulfillment, and follow-up.

What the Series A Has to Prove

The Teal Wand has passed major product gates: clinical validation, FDA authorization, and national launch. The Series A finances the less visible work of making those gates matter at scale. Prescriptions must be issued appropriately, kits delivered, samples processed, results returned, and abnormal findings handed back into care without losing the patient between systems.

That execution will determine how far at-home self-collection expands cervical cancer screening. Teal’s opportunity is large because the existing workflow leaves many people behind. Its obligation is equally specific: convenience has to remain connected to clinical performance and reliable follow-up as the service moves through payers, employers, providers, and health systems.

The $22M does not settle that question, and Teal has not disclosed the payer economics, unit economics, or adoption targets that would allow an outside reader to measure the national rollout. It gives the company more room to build the operating layer between a validated device and a completed screening. The next evidence will arrive through ordinary handoffs: a prescription issued, a kit delivered, a sample processed, a result understood, and a patient connected to the follow-up the screening requires.